. 2021 Jun 30;12:683913. doi: 10.3389/fimmu.2021.683913

Table 4.

Summary of the pooled ORs of two variants of CFB in patients with IgAN stage I or stage II.

	Allele model		Overdominant model		Dominant model		Heterozygote model		Homozygote model		Recessive model		OR_G (95% CI)
	OR (95% CI)	P_H	OR (95% CI)	P_H	OR (95% CI)	P_H	OR (95% CI)	P_H	OR (95% CI)	P_H	OR (95% CI)	P_H
rs549182
IgAN Stage I	1.33 (1.10,1.61)	0.003	0.88 (0.66,0.99)	0.040	1.30 (1.07,1.60)	0.010	1.25 (1.02,1.53)	0.032	4.03 (1.34,12.19)	0.013	3.90 (1.29,11.77)	0.016	1.31 (1.07,1.60)
IgAN stage II	1.19 (1.02,1.40)	0.031	1.0 (0.73,1.39)	0.979	0.94 (0.69,1.29)	0.716	0.99 (0.71,1.36)	0.937	0.41 (0.11,1.59)	0.197	0.41 (0.11,1.59)	0.197	0.94 (0.68,1.28)
IgAN Stage I and stage II	0.91 (0.68,1.22)	0.513	0.86 (0.72,1.02)	0.085	1.19 (1.00,1.41)	0.050	1.17 (0.98,1.39)	0.077	1.70 (0.80,3.61)	0.167	1.66 (0.78,3.52)	0.187	1.19 (1.01,1.41)
rs4151657
IgAN Stage I	1.13 (1.01,1.27)	0.031	0.80 (0.69,0.93)	0.003	1.25 (1.07,1.44)	0.004	1.28 (1.09,1.49)	0.002	1.11 (0.86,1.44)	0.417	0.99 (0.77,1.27)	0.928	1.18 (1.04,1.35)
IgAN stage II	1.21 (1.02,1.45)	0.033	0.77 (0.61,0.97)	0.029	1.35 (1.07,1.70)	0.012	1.36 (1.06,1.73)	0.014	1.30 (0.86,1.98)	0.217	1.12 (0.75,1.67)	0.584	1.28 (1.04,1.58)
IgAN Stage I and stage II	1.15 (1.05,1.27)	0.003	0.79 (0.70,0.90)	0.000	1.27 (1.12,1.44)	0.000	1.30 (1.14,1.48)	0.000	1.16 (0.93,1.45)	0.181	1.02 (0.83,1.26)	0.839	1.21 (1.08,1.35)